Maria Herthelius

TL;DR: Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome and was also associated with improvement in health-related quality of life.

TL;DR: A 2-year analysis found that the earlier clinical benefits achieved by eculizumab treatment of aHUS were maintained at 2 years of follow-up.

TL;DR: There was a high rate of recurrent febrile urinary tract infection in girls older than 1 year with dilating vesicoureteral reflux at study entry but not in boys, and antibiotic prophylaxis and endoscopic treatment decreased the infection rate.

TL;DR: The performance and simplicity of Schwartz formula are strong arguments for its routine use in children and adolescents, and the specific coefficient for children aged <13 years further improves this performance.

TL;DR: This prospective, open, randomized, controlled, multicenter study compared the rates of febrile urinary tract infection, kidney damage and reflux resolution in children with vesicoureteral reflux treated in 3 ways, including antibiotic prophylaxis, endoscopic therapy and surveillance with antibiotics only for symptomatic urinary tract infections.